glp 1 & gip GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Beyond the pancreas: contrasting cardiometabolic

En el Minuto de Salud hablamos con la autora principal del estudio.

Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies

Because metformin causes weight loss, in non-diabetics too

Since August, Ive lost 130 lbs

There is substantial evidence suggesting that AMPK is dysregulated in animals and humans with metabolic syndrome or T2D, and that AMPK activation (physiological or pharmacological) can improve insulin sensitivity and metabolic health

While GLP-1 RAs induce weight loss in diabetes, their metabolic impact in normoglycaemic PD patients appears limited